SynthesisRadiology2019
A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Synthesis in Radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease.AJNR. American journal of neuroradiology · 2025Guideline
- Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.Annals of internal medicine · 2020Pooled it
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Liver cancer · 2026Review
- [Expert consensus on overall standardized management of gadoxetate disodium-enhanced MRI examinations (version 2026)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents.Radiology · 2025Article
- Sodium thiosulfate for treatment of nephrogenic systemic fibrosis with metastatic pulmonary calcification in a patient undergoing peritoneal dialysis: a case report.BMC nephrology · 2025Article
- Article
- Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (version 3: revised may 20th, 2024).Japanese journal of radiology · 2025Article
- Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection.Journal of the Korean Society of Radiology · 2025Review
- Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (Version 3: Revised May 20th, 2024).Clinical and experimental nephrology · 2025Review
- Detection of acute pulmonary embolism using native repeated magnetic resonance imaging acquisitions under free-breathing and without respiratory or cardiac gating. A diagnostic accuracy study.European journal of radiology open · 2024Article
- A Primer for Utilizing Deep Learning and Abdominal MRI Imaging Features to Monitor Autosomal Dominant Polycystic Kidney Disease Progression.Biomedicines · 2024Review
- Coexistence of nephrogenic systemic fibrosis and calciphylaxis in a gadolinium-naïve, chronic haemodialysis patient.BMJ case reports · 2024Article
- Alone on a collagen island: Unique findings of osseous sclerotic bodies in nephrogenic systemic fibrosis.JAAD case reports · 2023Article
- Current state of pediatric neuro-oncology imaging, challenges and future directions.Neoplasia (New York, N.Y.) · 2023Review
- The road to breast cancer screening with diffusion MRI.Frontiers in oncology · 2023Review
- Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.Kidney international reports · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Although nephrogenic systemic fibrosis (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there continues to be limited knowledge because of the small number of patients with NSF. Purpose To perform a systematic review of NSF. Materials and Methods PubMed database was searched by using the term "Nephrogenic systemic fibrosis" from January 2000 to February 2019. Articles reporting details on individual patients with NSF diagnosis on the basis of both clinical presentations and biopsy confirmation were included. Data were pooled and authors were contacted for clarifications. Rates of NSF were compared through 2008 versus after 2008 and for group I versus group II GBCAs, assuming equal market share. Results Included were 639 patients from 173 articles. Data regarding sex were found for 295 men and 254 women. Age at NSF symptom onset was reported for 177 patients (mean, 49 years ± 16 [standard deviation]; age range, 6-87 years). There were 529 patients with documented exposure to GBCAs including gadodiamide (
Indexed as
Identifiers
31264946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.